The DEEP project has received research funding from the European Union under the 7th Framework Programme

News

DEEP-2: an update of the clinical centres involved

Ottobre 30, 2015
|
Comments off
|

Another step forward has been made toward the enrollment of new patients in the DEEP-2 study, a phase III multicentre, randomised, open label, non-inferiority active-controlled trial aiming at comparing for the first time the efficacy of deferiprone (DFP) vs deferasirox (DFX) in paediatric patients affected […]

Share
Read more →

QuBo, the multicenter observational transversal study for patients involved in the DEEP-2 trial

Ottobre 30, 2015
|
Comments off
|

The Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) has recently launched the multicenter observational transversal study “Quality evaluation of the informative booklets for patients involved in the DEEP-2 trial” (QuBo). The overall aim of this study is to investigate the quality of the informative material addressed to […]

Share
Read more →

The Story of the project as described in the Scientific report to the EC

Ottobre 30, 2015
|
Comments off
|

The most important achievements and activities carried out by the project have been collected and included in the DEEP Scientific Report related to the period from 01/01/2014 to 30/06/2015 which has been submitted to the European Commission on September 2015.

The report provided a […]

Share
Read more →

DEEP-3: an update on the observational study

Ottobre 30, 2015
|
Comments off
|

DEEP-3 is a long-term observational safety study which evaluates the nature and incidence of adverse effects of deferiprone (DFP) in children and adolescents with beta-thalassaemia major and currently involves 18 recruiting centres from 7 different countries: Albania, Cyprus, Greece, Egypt, Italia, Morocco and Tunisia.

On […]

Share
Read more →